ATTR-ACT
2018
Tafamidis in Transthyretin Amyloid Cardiomyopathy
In 441 patients with transthyretin amyloid cardiomyopathy, tafamidis reduced all-cause mortality and cardiovascular hospitalisation compared with placebo.
Result
Efficacy: All-cause mortality + CV hospitalisationHR 0.7
Below 1 favours tafamidis, above 1 favours placebo.
Also reported: Fewer CV hospitalisations.
- Subtopic
- Cardiomyopathy
- Design
- Double-blind RCT
- Relevance
- Practice-defining: a trial the guidelines cite as evidence.
- Source
- Maurer MS, et al. N Engl J Med. 2018;379(11):1007-1016.doi 10.1056/NEJMoa1805689
Discussion & critique
First disease-modifying therapy for ATTR cardiomyopathy. Survival curves separate only after ~ 18 months; cost and the need for early diagnosis limit reach.